公开(公告)号：US20160280758A1

公开(公告)日：2016-09-29

申请号：US15082986

申请日：2016-03-28

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  C07K14/725 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20160279216A1

公开(公告)日：2016-09-29

申请号：US15082978

申请日：2016-03-28

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: A61K39/00 ,  G01N33/569 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  C07K14/47 ,  C07K14/725

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20160272724A1

公开(公告)日：2016-09-22

申请号：US14442320

申请日：2013-11-12

Applicant: INVECTYS

Inventor： Maria de las Nieves LOUSTAU ,  Julien CAUMARTIN ,  Pierre LANGLADE-DEMOYEN

IPC: C07K16/34 ,  A61K39/00

CPC classification number: C07K16/34 ,  A61K39/0005 ,  A61K2039/53 ,  A61K2039/585 ,  C07K14/70539 ,  C07K16/2833 ,  C07K2317/24 ,  C07K2317/76

Abstract: An antibody or antigen-binding fragment thereof which specifically binds the α3 domain of a HLA-G protein, in particular binds the β2-microglobulin free HLA-G protein exhibiting an α3 domain. The nucleic acid molecules encoding a human HLA-G α3 domain polypeptide, which is selected from a group of specific sequences, and vectors for the cloning and/or expression of such nucleic acid molecules, recombined cells or cell lines and compositions for use in a host in need thereof to interfere with and neutralize the immune down-regulation due to HLA-G proteins, and/or improving or treating conditions showing HLA-G+ lesions, and/or improving or treating a neoplasic condition or disease. A method of producing the antibody or antigen-binding fragment thereof, immunogenic compositions for use to elicit in a host an immune response against the α3 domain of HLA-G protein, and an in vitro method for detecting HLA-G protein in a sample are also described.

Abstract translation: 特异性结合HLA-G蛋白的α3结构域的抗体或其抗原结合片段特别结合表现出α3结构域的不含β2-微球蛋白的HLA-G蛋白。 编码人类HLA-Gα3结构域多肽的核酸分子，其选自一组特定序列，以及用于克隆和/或表达此类核酸分子的载体，重组细胞或细胞系和用于 需要它的宿主干扰和中和由于HLA-G蛋白引起的免疫下调，和/或改善或治疗显示HLA-G +损伤的病症，和/或改善或治疗新生病症或疾病。 制备抗体或其抗原结合片段的方法，用于在宿主中引发针对HLA-G蛋白的α3结构域的免疫应答的免疫原性组合物和用于检测样品中HLA-G蛋白的体外方法 也描述。

公开(公告)号：US20160271239A1

公开(公告)日：2016-09-22

申请号：US15034496

申请日：2014-10-31

Applicant: BAVARIAN NORDIC A/S

Inventor： SUSAN FOY ,  STEFANIE MANDL ,  RYAN ROUNTREE ,  ALAIN DELCAYRE

IPC: A61K39/00 ,  A61K39/395 ,  C12N7/00

CPC classification number: A61K39/0011 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/585 ,  C12N7/00 ,  C12N2710/24034 ,  C12N2710/24043 ,  C12N2710/24071 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24171 ,  A61K2300/00

Abstract: The present disclosure encompasses therapies, compositions, and methods for treatment of a human cancer patient using a recombinant poxvirus encoding a tumor-associated antigen in combination with one or more agonists or antagonists of immune checkpoint inhibitors.

Abstract translation: 本公开包括使用编码肿瘤相关抗原的重组痘病毒与免疫检查点抑制剂的一种或多种激动剂或拮抗剂联合治疗人类癌症患者的治疗，组合物和方法。

公开(公告)号：US09415096B2

公开(公告)日：2016-08-16

申请号：US14729752

申请日：2015-06-03

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Yasuharu Nishimura ,  Kazunori Yokomine ,  Takuya Tsunoda ,  Yusuke Nakamura

IPC: A61K38/00 ,  A61K39/00 ,  C12N5/0783 ,  C07K7/08 ,  C07K7/06

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/06 ,  C07K7/08 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/998 ,  C12N2502/11

Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.

公开(公告)号：US20160229896A1

公开(公告)日：2016-08-11

申请号：US15098210

申请日：2016-04-13

Applicant: TheVax Genetics Vaccine Co., Ltd.

Inventor： WEI-I CHOU ,  Chia-Mao Wu ,  Jiun-Ming Wu ,  Hsiu-Kang Chang

IPC: C07K14/005 ,  C12N9/14 ,  A61K39/135 ,  A61K39/17 ,  A61K39/12 ,  C12N9/10 ,  C07K14/81

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/135 ,  A61K39/17 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K39/385 ,  A61K2039/57 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/21 ,  C07K14/70596 ,  C07K14/81 ,  C07K2319/02 ,  C07K2319/04 ,  C07K2319/095 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/1077 ,  C12N9/14 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2750/10022 ,  C12N2750/10034 ,  C12N2760/18134 ,  C12N2770/24222 ,  C12N2770/24234 ,  C12N2770/24334 ,  C12N2770/32134 ,  C12Y204/02036 ,  C12Y306/05002 ,  Y02A50/386

Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

Abstract translation: 公开了包含用于诱导增强的病原体抗原特异性T细胞应答的融合蛋白的疫苗组合物。 融合蛋白包括：（a）位于融合蛋白N末端的抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （b）长度为34-112个氨基酸残基的易位肽，其包含与SEQ ID NO：4,2,3或6至少90％相同的氨基酸序列，位于SEQ ID NO： APC结合结构域或CD91受体结合结构域; 和（c）位于移位肽的C末端的病原体的抗原; （d）包含SEQ ID NO：13的氨基酸序列的核出口信号; 和（e）位于融合蛋白C末端的内质网保持序列。

公开(公告)号：US09402895B2

公开(公告)日：2016-08-02

申请号：US13334657

申请日：2011-12-22

Applicant: Yuan Chang ,  Patrick S. Moore

Inventor： Yuan Chang ,  Patrick S. Moore

IPC: A01N63/00 ,  A01N65/00 ,  A61K48/00 ,  A61K39/245 ,  C07K14/005 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/245 ,  A61K39/12 ,  A61K2039/54 ,  A61K2039/55505 ,  A61K2039/585 ,  C07K14/005 ,  C07K2319/60 ,  C12N7/00 ,  C12N2710/16422 ,  C12N2710/16434 ,  C12N2710/16471

Abstract: An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein.

Abstract translation: 提供免疫增强的卡波西肉瘤相关的疱疹病毒潜伏相关核抗原1（“KSHV LANA1”）多肽和引发对KSHV LANA1的免疫应答的相关方法。 本文还描述了当与蛋白质连接或掺入蛋白质时能够抑制蛋白质降解或延缓蛋白质合成的新型多肽。

公开(公告)号：US09381236B2

公开(公告)日：2016-07-05

申请号：US14741107

申请日：2015-06-16

Applicant: The Regents of the University of California

Inventor： Daniel A. Portnoy ,  Anat A. Herskovits ,  Gregory Crimmins

IPC: A61K39/02 ,  A61K39/00

CPC classification number: A61K39/0208 ,  A61K39/00 ,  A61K39/02 ,  A61K2039/52 ,  A61K2039/522 ,  A61K2039/58 ,  A61K2039/585

Abstract: Mutant Listeria bacteria that modulate interferon-β production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.

Abstract translation: 调节干扰素的突变型李斯特菌 提供生产。 本发明细菌的特征在于在选自TetR基因，LadR基因，VirR基因，MarR基因，MdrL基因，MdrT基因和MdrM基因的基因中具有突变。 主题细菌可用于各种应用，其中感兴趣的代表性应用包括但不限于：（a）使用受试细菌作为佐剂; （b）使用受试细菌作为将大分子引入细胞的递送载体; （c）使用受试细菌作为引发或增强细胞免疫应答的疫苗; 等等

公开(公告)号：US20160187340A1

公开(公告)日：2016-06-30

申请号：US14927802

申请日：2015-10-30

Applicant: Dana-Farber Cancer Institute, Inc. ,  Consejo Nactional De Investigaciones Cientificias Y Tecnicas ,  Fundacion Sales

Inventor： Margaret A. Shipp ,  Przemyslaw Juszczynski ,  Jing Ouyang ,  Jeffery L. Kutok ,  Scott J. Rodig ,  Gabriel Rabinovich

IPC: G01N33/574 ,  C07K16/30 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28

CPC classification number: G01N33/57407 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/585 ,  C07K16/28 ,  C07K16/3061 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/5011 ,  G01N2333/47 ,  G01N2500/00

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.

公开(公告)号：US09339536B2

公开(公告)日：2016-05-17

申请号：US14095947

申请日：2013-12-03

Applicant: TheVax Genetics Vaccine Co., Ltd.

Inventor： Wei-I Chou ,  Chia-Mao Wu ,  Jiun-Ming Wu ,  Hsiu-Kang Chang

IPC: C07K14/21 ,  C07K19/00 ,  A61K39/02 ,  A61K39/385 ,  A61K39/21 ,  C07K14/005 ,  A61K47/48 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/135 ,  A61K39/17 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K39/385 ,  A61K2039/57 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/21 ,  C07K14/70596 ,  C07K14/81 ,  C07K2319/02 ,  C07K2319/04 ,  C07K2319/095 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/1077 ,  C12N9/14 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2750/10022 ,  C12N2750/10034 ,  C12N2760/18134 ,  C12N2770/24222 ,  C12N2770/24234 ,  C12N2770/24334 ,  C12N2770/32134 ,  C12Y204/02036 ,  C12Y306/05002 ,  Y02A50/386

Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

Abstract translation: 公开了包含用于诱导增强的病原体抗原特异性T细胞应答的融合蛋白的疫苗组合物。 融合蛋白包括：（a）位于融合蛋白N末端的抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （b）长度为34-112个氨基酸残基的易位肽，其包含与SEQ ID NO：4,2,3或6至少90％相同的氨基酸序列，位于SEQ ID NO： APC结合结构域或CD91受体结合结构域; 和（c）位于移位肽的C末端的病原体的抗原; （d）包含SEQ ID NO：13的氨基酸序列的核出口信号; 和（e）位于融合蛋白C末端的内质网保持序列。